Scynexis INC

SCYNEXIS, Inc. successfully obtained shareholder approval to increase its authorized common stock to 60 million shares.

SCYNEXIS, Inc. has implemented a one-for-eight reverse stock split effective May 29, 2026, to adjust its capital structure.

SCYNEXIS, Inc. stockholders approved a reverse stock split, with the Board setting a 1-for-8 ratio effective May 29, 2026.

SCYNEXIS, Inc. director Dr. Steven C. Gilman will retire and not stand for reelection at the 2026 Annual Meeting.

SCYNEXIS, Inc. announced the acquisition of global rights for SCY-770, a Phase 2-ready asset for Autosomal Dominant Polycystic Kidney Disease (ADPKD), alongside a $40 million PIPE financing to extend its cash runway.

SCYNEXIS, Inc. announced a $40.0 million private placement of common stock and warrants, extending its operational funding into mid-2029.

SCYNEXIS reported a wider net loss in Q3 2025, driven by reduced license revenue, while advancing its SCY-247 antifungal program and securing a $24.8 million payment from GSK following the termination of the MARIO study.

SCYNEXIS reported a significant reduction in net loss for Q2 2025, driven by a warrant liability fair value adjustment, while navigating a dispute with GSK over the MARIO study and a Nasdaq minimum bid price deficiency.

SCYNEXIS is in disagreement with GSK over the termination of the MARIO study for invasive candidiasis treatment, despite the FDA lifting the clinical hold.

SCYNEXIS reports its Q3 2024 financial results, impacted by a product recall and clinical hold, while also detailing ongoing legal proceedings and strategic updates.

SCYNEXIS, Inc. reported its second quarter 2024 financial results, which were significantly impacted by a product recall and clinical hold on its lead drug, ibrexafungerp, while also detailing ongoing legal proceedings and strategic adjustments.

SCYNEXIS reported its first quarter 2024 financial results, which were significantly impacted by a product recall and clinical hold related to its lead drug, ibrexafungerp.

SCYNEXIS, Inc. reported a net loss of $8.6 million for FY2025, terminated the MARIO study with GSK for a $24.8 million payment, and is advancing its second-generation antifungal SCY-247 into Phase 1 IV and Phase 2 oral trials.

SCYNEXIS's 2024 results highlight a year of transition, marked by a BREXAFEMME recall, progress in clinical development, and strategic focus on antifungal innovation.

Scynexis and GlaxoSmithKline have amended their exclusive license agreement for ibrexafungerp, adjusting milestone payments and responsibilities following a manufacturing issue that led to a product recall and clinical hold.

SCYNEXIS Inc. reports a Form 4 filing detailing director Brian Philippe Tinmouth's acquisition of 2,875 shares and exercise of stock options.

SCYNEXIS Inc. reports a Form 4 filing detailing stock transactions by Director Guy Macdonald.

SCYNEXIS INC reports a Form 4 filing detailing director David C. Hastings' acquisition of common stock and stock options.

SCYNEXIS INC reports a Form 4 filing detailing a director's acquisition of common stock and stock options.

SCYNEXIS Chief Financial Officer Ivor Macleod IV was granted 129,833 restricted stock units, increasing his beneficial ownership.

SCYNEXIS Chief Legal Officer Scott Sukenick was granted 129,833 restricted stock units, vesting over three years starting February 28, 2026.

SCYNEXIS, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, auditor ratification, executive compensation, and significant increases in authorized common stock and equity incentive plan shares.

SCYNEXIS, Inc. has scheduled a special meeting for May 19, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq minimum bid price requirements.

SCYNEXIS, INC. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

SCYNEXIS, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.

SCYNEXIS, INC. has filed a definitive proxy statement with the SEC.

SCYNEXIS, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 19, 2024, to address key proposals including director elections, auditor ratification, executive compensation, and approval of an equity incentive plan.

Federated Hermes, Inc. and related entities report a 4.03% beneficial ownership stake in SCYNEXIS Inc. as of June 30, 2026.

Federated Hermes, Inc. and associated entities report a 4.45% beneficial ownership stake in SCYNEXIS Inc. common stock as of June 30, 2026.

CVI Investments, Inc. and Heights Capital Management, Inc. report a combined 6.2% stake in SCYNEXIS, Inc. as of March 31, 2026.

CVI Investments, Inc. and Heights Capital Management, Inc. report combined beneficial ownership of 6.7% of SCYNEXIS, Inc. common stock.

Squadron Master Fund LP, along with its affiliates, has disclosed beneficial ownership of 7,608,695 shares, representing 9.6% of Scynexis Inc.'s common stock.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 9.99% of Scynexis, Inc.'s common stock as of March 31, 2026.